Objective:

To present new clinical and real-world data on the TECNIS PureSee intraocular lens (IOL), highlighting its performance at the 2026 ASCRS Annual Meeting.

Approach:

Key Findings:

• Distance-corrected intermediate vision reached a mean of 20/28 (monocular).
• Patients gained approximately 1.5 lines of near vision versus control.
• Visual disturbance rates were reported as low.
• 94% of patients maintained distance-corrected visual acuity of 20/25 or better within ±0.5 D defocus.
• Mean binocular uncorrected distance vision of approximately 20/19 in real-world evidence.
• High rates of spectacle independence for distance (96%) and intermediate (95%).
• Patient satisfaction exceeded 90%.
• Performance appeared independent of pupil size.

Interpretation:

The TECNIS PureSee EDOF IOL demonstrates strong performance in distance and intermediate vision compared to monofocal lenses, with high patient satisfaction and low rates of visual disturbances.

Limitations:

• The studies may have selection bias due to the nature of clinical trials and observational studies.
• Long-term outcomes and effects on near vision require further investigation.
• The studies may not fully represent all patient demographics.

Conclusion:

The TECNIS PureSee IOL shows promising results in enhancing visual performance and patient satisfaction, supporting its use in clinical practice due to its innovative design.

Sources:

• ASCRS Annual Meeting 2026
Attribution Notice

This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.